Profitelligence Profitelligence · Filing Ledger Open RVTY research →

Form 8-K · Current Report · Filed 2026-05-05

Revvity Reports Q1 2026 Financial Results and Announces China Immunodiagnostics Divestiture

Revvity, Inc. reported its financial results for the first quarter of 2026, showing a revenue of $711 million, GAAP EPS from continuing operations of $0.37, and adjusted EPS from continuing operations of $1.06. The company also announced its intention to divest its China Immunodiagnostics business, with a definitive agreement expected in Q2 2026 and the divestiture expected to close in 2027. Pro forma financial results, excluding the China Immunodiagnostics business, showed revenue of $687 million, GAAP EPS from continuing operations of $0.40, and adjusted EPS from continuing operations of $1.04. The company provided full-year 2026 guidance on a pro forma basis, forecasting total revenue of $2.81-$2.84 billion, pro forma organic revenue growth of 3%-4%, and pro forma adjusted EPS of $5.20-$5.30.

Filer
Revvity Inc. RVTY · NYSE
Filed
Accession
0000031791-26-000016
CIK
0000031791
Signal
High impactHealthcare

Items reported

Item events

Reported Item

Financial Instrument Agreement Divestiture Agreement Earnings Beat General Statement Non-Compliance Notice

Market reaction

Close before filing

$86.51

Next session

+14.5%

Since filing

+69.6%

Latest close

$146.73

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from RVTY reporting the same item, with the next session's move:

Revvity, Inc. Shareholders Approve Key By-law Amendments-0.1%
Revvity, Inc. Announces Financial Results for Q4 and Full Year 2025-7.0%
Revvity Announces Preliminary Q4 2025 Results and Upcoming J.P. Morgan Presentation+7.3%

About Revvity Inc.

Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use. The company operates through two main segments: Life Sciences and Diagnostics, serving customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations. Its portfolio includes reagents, consumables, assays, instruments, software, and specialized services that support workflows from discovery through diagnosis. Revvity focuses on areas such as translational multi-omics, biomarker identification, imaging, screening, detection, informatics, reproductive health, immunodiagnostics, and genomic testing. It also supports applications in rare disease testing, newborn screening, hereditary cancer, and broader clinical laboratory services. Based in Waltham, Massachusetts, Revvity plays an important role in the healthcare and life sciences ecosystem by helping researchers, clinicians, and laboratories generate and analyze data across a wide range of scientific and diagnostic applications.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another RVTY filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts